Clinical Trials Browser

Phase 1/2 × surufatinib × 1 year × Clear all

Ovarian Neoplasms

NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

Phase 1/2 Completed

36 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Clinical Trials

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Open-label Study of Surufatinib in Japanese Patients

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors